To evaluate the time to progression in women with hormone responsive advanced breast cancer treated with combination of exemestane and fulvestrant. Every 2 cycles [clinicaltrials_resource:19bce414dbe6783c42acc7201a68c5f0]
Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To evaluate the time to progression in women with hormone responsive advanced breast cancer treated with combination of exemestane and fulvestrant. Every 2 cycles [clinicaltrials_resource:19bce414dbe6783c42acc7201a68c5f0]
Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
Bio2RDF identifier
19bce414dbe6783c42acc7201a68c5f0
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:19bce414dbe6783c42acc7201a68c5f0
measure [clinicaltrials_vocabulary:measure]
To evaluate the time to progre ...... of exemestane and fulvestrant.
time frame [clinicaltrials_vocabulary:time-frame]
Every 2 cycles
description
Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
identifier
clinicaltrials_resource:19bce414dbe6783c42acc7201a68c5f0
title
To evaluate the time to progre ...... nd fulvestrant. Every 2 cycles
@en
type
label
To evaluate the time to progre ...... ce414dbe6783c42acc7201a68c5f0]
@en